Amgen loses bid to delay Neupogen biosimilar entry

23-03-2015

A judge at the US District Court for the Northern District of California has denied Amgen’s attempt to block entry of a biosimilar version of its drug Neupogen (filgrastim).


Amgen, Sandoz, Neupogen, biosimilar, US District Court for the Northern District of California

LSIPR